



PRESS RELEASE

Not For Distribution in the United States

## SUCCESSFUL COMPLETION OF CEGEDIM'S €180.5M CAPITAL INCREASE AND ACQUISITION OF A STAKE IN THE CAPITAL SHARE BY THE FSI

**Paris, December 15, 2009** – Cegedim, the world leader in life sciences CRM, announced the great success of the share capital increase with preferential subscription rights launched on November 20, 2009.

Total request amounted to about 6 million shares, which represents an oversubscription of 129%. The final gross proceeds amounting to €180.5M, corresponding to the issue of 4,665,724 new shares.

The capital increase, as well as the presence of the FSI as a new shareholder allows Cegedim to benefit from substantial resources in order to accelerate its dynamic external growth policy. The Group intends to undertake a series of medium-sized acquisitions and in particular to strengthen the "*Healthcare Professionals*" sector. Cegedim has already initiated a number of contacts with key targets.

Cegedim wishes to thank all its shareholders for the confidence and support they have demonstrated in the Group's strategy and future outlook by taking up their allocations.

Settlement and delivery of the new shares will take place on December 17, 2009. The listing of the new shares on Euronext Paris on the same quotation line as the existing shares (ISIN code:FR0000053506) will also take place as December 17, 2009. As from this date, the capital of Cegedim SA will be composed of 13,997,173 shares.

CALYON and Société Générale Corporate & Investment Banking were in charge of this operation as Lead Managers and Joint Bookrunners.

The French language prospectus has been approved by the *Autorité des marchés financiers* (the "AMF") on November 20, 2009 under visa number 09-340.

### **About Cegedim:**

Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases. Its offerings are targeted notably at healthcare industries, life sciences companies, healthcare professionals and insurance companies. The world leader in life sciences CRM, Cegedim is also one of the leading suppliers of strategic healthcare industry data. Cegedim employs 8,200 people in more than 80 countries and generated revenue of €849 million in 2008.

Cegedim SA is listed in Paris (EURONEXT: CGM).

To learn more, please visit: [www.cegedim.com](http://www.cegedim.com)

**Media inquiries**

**Cegedim**  
Aude Balleydier  
Media Relations  
Tel: + 33 (0)1 49 09 68 81  
[aude.balleydier@cegedim.fr](mailto:aude.balleydier@cegedim.fr)

**Presse & Papiers Agency**  
Guillaume de Chamisso  
Press Officer  
Tel: + 33 (0)1 77 35 60 99  
[guillaume.dechamisso@pressepapiers.fr](mailto:guillaume.dechamisso@pressepapiers.fr)

**Investor relations**

**Cegedim**  
Jan Eryk Umiastowski  
Chief Investment Officer – Investor relations  
Tel: + 33 (0)1 49 09 33 36  
[investor.relations@cegedim.fr](mailto:investor.relations@cegedim.fr)

---

**Disclaimer:**

This document is not an offer for sale of securities in the United States. The securities referred to herein may not be offered or sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended. Any public offering of securities in the United States will be made by means of a prospectus that may be obtained from the Issuer and that will contain detailed information about the Company and its management, as well as financial statements. The Company does not intend to register any portion of the offering of the securities in the United States. This announcement is not being made in and may not be distributed or sent into the United States.

This Press Release is for information only and does not constitute or form part of any offer or invitation to issue, acquire or dispose of any securities or investment advice in any jurisdiction.

This Press Release is an advertisement and not a prospectus and investors should not subscribe for or purchase any shares referred to in this Press Release in connection with the rights issue.

Past performance is no guide to future performance and persons needing advice should consult an independent financial adviser. Any indication in this Press Release of the price at which shares of the Company have been bought or sold in the past cannot be relied upon as a guide to future performance. No statement in this Press Release is intended to be a profit forecast.